Frontiers in Pharmacology (Aug 2021)
An Overview of Cell-Based Assay Platforms for the Solute Carrier Family of Transporters
- Vojtech Dvorak,
- Tabea Wiedmer,
- Alvaro Ingles-Prieto,
- Patrick Altermatt,
- Helena Batoulis,
- Felix Bärenz,
- Eckhard Bender,
- Daniela Digles,
- Franz Dürrenberger,
- Laura H. Heitman,
- Adriaan P. IJzerman,
- Douglas B. Kell,
- Douglas B. Kell,
- Stefanie Kickinger,
- Daniel Körzö,
- Philipp Leippe,
- Thomas Licher,
- Vania Manolova,
- Riccardo Rizzetto,
- Francesca Sassone,
- Lia Scarabottolo,
- Avner Schlessinger,
- Vanessa Schneider,
- Hubert J. Sijben,
- Anna-Lena Steck,
- Hanna Sundström,
- Sara Tremolada,
- Maria Wilhelm,
- Marina Wright Muelas,
- Diana Zindel,
- Claire M. Steppan,
- Giulio Superti-Furga,
- Giulio Superti-Furga
Affiliations
- Vojtech Dvorak
- CeMM Research Center for Molecular Medicine of the Austrian Academy of Sciences, Vienna, Austria
- Tabea Wiedmer
- CeMM Research Center for Molecular Medicine of the Austrian Academy of Sciences, Vienna, Austria
- Alvaro Ingles-Prieto
- CeMM Research Center for Molecular Medicine of the Austrian Academy of Sciences, Vienna, Austria
- Patrick Altermatt
- Vifor (International), St. Gallen, Switzerland
- Helena Batoulis
- Drug Discovery Sciences–Lead Discovery, Bayer Pharmaceuticals, Wuppertal, Germany
- Felix Bärenz
- Sanofi-Aventis Deutschland GmbH, Frankfurt am Main, Germany
- Eckhard Bender
- Drug Discovery Sciences–Lead Discovery, Bayer Pharmaceuticals, Wuppertal, Germany
- Daniela Digles
- Department of Pharmaceutical Sciences, University of Vienna, Vienna, Austria
- Franz Dürrenberger
- Vifor (International), St. Gallen, Switzerland
- Laura H. Heitman
- Division of Drug Discovery and Safety, LACDR, Leiden University, Leiden, Netherlands
- Adriaan P. IJzerman
- Division of Drug Discovery and Safety, LACDR, Leiden University, Leiden, Netherlands
- Douglas B. Kell
- Department of Biochemistry and Systems Biology, Institute of Systems, Molecular and Integrative Biology, University of Liverpool, Liverpool, United Kingdom
- Douglas B. Kell
- Novo Nordisk Foundation Centre for Biosustainability, Technical University of Denmark, Kgs. Lyngby, Denmark
- Stefanie Kickinger
- Department of Pharmaceutical Sciences, University of Vienna, Vienna, Austria
- Daniel Körzö
- Department of Pharmaceutical Sciences, University of Vienna, Vienna, Austria
- Philipp Leippe
- Department of Chemical Biology, Max Planck Institute for Medical Research, Heidelberg, Germany
- Thomas Licher
- Sanofi-Aventis Deutschland GmbH, Frankfurt am Main, Germany
- Vania Manolova
- Vifor (International), St. Gallen, Switzerland
- Riccardo Rizzetto
- 0Axxam SpA, Bresso (Milano), Italy
- Francesca Sassone
- 0Axxam SpA, Bresso (Milano), Italy
- Lia Scarabottolo
- 0Axxam SpA, Bresso (Milano), Italy
- Avner Schlessinger
- 1Department of Pharmacological Sciences, Icahn School of Medicine at Mount Sinai, New York, NY, United States
- Vanessa Schneider
- Department of Pharmaceutical Sciences, University of Vienna, Vienna, Austria
- Hubert J. Sijben
- Division of Drug Discovery and Safety, LACDR, Leiden University, Leiden, Netherlands
- Anna-Lena Steck
- Vifor (International), St. Gallen, Switzerland
- Hanna Sundström
- Vifor (International), St. Gallen, Switzerland
- Sara Tremolada
- 0Axxam SpA, Bresso (Milano), Italy
- Maria Wilhelm
- Vifor (International), St. Gallen, Switzerland
- Marina Wright Muelas
- Department of Biochemistry and Systems Biology, Institute of Systems, Molecular and Integrative Biology, University of Liverpool, Liverpool, United Kingdom
- Diana Zindel
- Drug Discovery Sciences–Lead Discovery, Bayer Pharmaceuticals, Wuppertal, Germany
- Claire M. Steppan
- 2Pfizer Worldwide Research, Development and Medical, Groton, MA, United States
- Giulio Superti-Furga
- CeMM Research Center for Molecular Medicine of the Austrian Academy of Sciences, Vienna, Austria
- Giulio Superti-Furga
- 3Center for Physiology and Pharmacology, Medical University of Vienna, Vienna, Austria
- DOI
- https://doi.org/10.3389/fphar.2021.722889
- Journal volume & issue
-
Vol. 12
Abstract
The solute carrier (SLC) superfamily represents the biggest family of transporters with important roles in health and disease. Despite being attractive and druggable targets, the majority of SLCs remains understudied. One major hurdle in research on SLCs is the lack of tools, such as cell-based assays to investigate their biological role and for drug discovery. Another challenge is the disperse and anecdotal information on assay strategies that are suitable for SLCs. This review provides a comprehensive overview of state-of-the-art cellular assay technologies for SLC research and discusses relevant SLC characteristics enabling the choice of an optimal assay technology. The Innovative Medicines Initiative consortium RESOLUTE intends to accelerate research on SLCs by providing the scientific community with high-quality reagents, assay technologies and data sets, and to ultimately unlock SLCs for drug discovery.
Keywords
